SELLAS Life Sciences (SLS) Enterprise Value (2010 - 2026)
SELLAS Life Sciences (SLS) posted quarterly Enterprise Value of -$107.1 million for Q1 2026, down 107000.0% year-over-year from N/an in Q1 2025, and down 107000.0% quarter-over-quarter from -$100000.0 in Q4 2025.
SELLAS Life Sciences (SLS) Enterprise Value (2010 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has reported Enterprise Value for 17 consecutive years, with -$107.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value fell 107000.0% year-over-year to -$107.1 million; the TTM figure through Mar 2026 stood at -$107.1 million (down 107000.0% YoY), while the FY2025 annual figure was -$100000.0, up 99.28% from the prior year.
- Enterprise Value declined to -$107.1 million in Q1 2026 per SLS's latest filing, from -$100000.0 in the prior quarter.
- Across five years, Enterprise Value topped out at -$100000.0 in Q1 2022 and bottomed at -$107.1 million in Q1 2026.
- Historically, Enterprise Value has averaged -$15.7 million across 5 years, with a median of -$4.0 million in 2023.
- Annual changes were most pronounced in 2022 — Enterprise Value soared 99.62% — and 2026, when it sank 107000.0%.
- SELLAS Life Sciences' Enterprise Value stood at -$17.1 million in 2022, then surged by 99.42% to -$100000.0 in 2023, then sank by 13786.0% to -$13.9 million in 2024, then jumped by 99.28% to -$100000.0 in 2025, then tumbled by 107000.0% to -$107.1 million in 2026.
- Business Quant data shows SLS's Enterprise Value at -$107.1 million in Q1 2026, -$100000.0 in Q4 2025, and -$44.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | SELLAS Life Sciences | 2.32 Bn | 2.18 Bn | - | -138.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -138.34 Mn |
| Mar 31, 2026 | -107.10 Mn |
| Dec 31, 2025 | -100,000.00 |
| Sep 30, 2025 | -44.30 Mn |
| Jun 30, 2025 | -25.30 Mn |
| Mar 31, 2025 | -100,000.00 |
| Dec 31, 2024 | -13.89 Mn |
| Sep 30, 2024 | -21.03 Mn |
| Jun 30, 2024 | -9.10 Mn |
| Mar 31, 2024 | -100,000.00 |
| Dec 31, 2023 | -100,000.00 |
| Sep 30, 2023 | -4.00 Mn |
| Jun 30, 2023 | -100,000.00 |
| Mar 31, 2023 | -23.90 Mn |
| Dec 31, 2022 | -17.13 Mn |
| Sep 30, 2022 | -100,000.00 |
| Jun 30, 2022 | -100,000.00 |
| Mar 31, 2022 | -100,000.00 |
| Dec 31, 2021 | -100,000.00 |
| Sep 30, 2021 | -26.28 Mn |